A new investigational, orally inhaled therapy has been found effective in treating migraines, according to researchers.
The research team from Thomas Jefferson University Hospital in Philadelphia, Pennsylvania have shown that LEVADEX provided pain relief in 30 minutes and sustained relief for 48 hours.
The study participants reported significant relief from symptoms such as pain, nausea and light and sound sensitivity when compared to placebo treatment.
According to trial results, this therapy provided pain relief in 30 minutes and sustained relief for 48 hours after dosing in patients with moderate or severe migraine attacks.
The drug was generally very well tolerated and there were no drug-related, serious adverse events reported.
Migraine is a common, debilitating neurological disorder and common associated symptoms of migraine include nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound).
"The major advantage of LEVADEX is that it has the efficacy of intravenous DHE (dihydroergotamine) with a side-effect profile similar to placebo and better than oral triptans," said Dr Stephen Silberstein, F.A.C.P, a clinical study investigator, director of the Jefferson Headache Center, and professor in the Department of Neurology at Jefferson Medical College of Thomas Jefferson University.